Neograft Technologies Raises $3M in Equity Financing
Summary
Neograft Technologies, Inc., a Pittsburgh, PA-based developer of medical devices that treat coronary artery disease, has raised $3m in equity financing., a Pittsburgh, PA-based developer of medical devices that treat coronary artery disease, has raised $3m in filing with the S.E.C., the investment was made by 5 backers.According to a, the investment was made by 5 backers.Led by CEO David Wagner, NeoGraft is currently developing its first product, Angioshield®, a new device to be used for controlled structural support to veins intended for use in bypass procedures as arterial vein grafts (AVGs).The system, which is not approved for use in the USA, is designed to allow clinicians to achieve superior outcomes for treatment of coronary and peripheral arterial re-vascularization.